DSIP (Delta Sleep-Inducing Peptide)

An Antibody Reports What It Binds, Not What Is There

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Radioimmunoassay quantifies how much material in a sample competes with a labelled standard for antibody binding. It measures immunoreactivity, which is what an antibody recognises, not necessarily the molecule the antibody was raised against.

Key facts

Measures
Competition for antibody binding
Reports
Immunoreactivity
Does not establish
Molecular identity
Cross-reactivity
Any molecule sharing the epitope
Standard hedge
'-like material', 'immunoreactive X'
Confirmation requires
Chromatography, mass spectrometry

How the method works

A known quantity of labelled peptide and an antibody are mixed with the sample. Anything in the sample that binds the antibody displaces some labelled peptide, and the amount displaced is converted into a concentration. It is sensitive, it scales well, and it was the workhorse of peptide endocrinology for decades.

What the antibody actually recognises

An epitope, a small region of the molecule, often only a handful of residues. Anything presenting that region will bind, whether it is the intended peptide, a fragment containing it, a larger precursor, or an unrelated molecule that happens to display a similar surface. The assay cannot distinguish between them, because binding is all it measures.

Research material referenced

DSIP 5mg, third-party HPLC tested

Buy DSIP · £13.95

Why the hedged phrasing exists

Careful authors write DSIP-like material or immunoreactive DSIP rather than DSIP. That is not stylistic caution. It is a precise statement that the assay detected something the antibody bound, and that identity was not established. Where a paper uses the hedge and a summary of it drops the hedge, the claim has been strengthened without any new evidence.

How the ambiguity gets resolved

By separating the sample before measuring it. Chromatography sorts material by size, so running immunoreactive fractions on a column shows whether the signal sits where the peptide should. If it appears at a much larger size, the antibody is binding something else. Mass spectrometry settles identity outright.

Why this matters for the DSIP literature specifically

Most of the tissue distribution work behind this compound's reputation was generated by radioimmunoassay in the 1980s. Whether those measurements identified the peptide or a family of larger molecules sharing an epitope is a question the method cannot answer on its own, and one the original authors examined directly.

What this is not

A criticism of the technique or of the researchers who used it. Radioimmunoassay was and is a legitimate and sensitive method, and the people who used it generally stated its limits accurately. The problem arises downstream, where careful phrasing is discarded by people summarising the work.

Frequently asked questions

What does a radioimmunoassay measure?

How much material competes with a labelled standard for antibody binding, immunoreactivity, not molecular identity.

Why do papers say 'DSIP-like material'?

It is a precise hedge meaning the antibody bound something, and identity was not established.

How is identity confirmed?

Chromatography to check the signal appears at the right size, and mass spectrometry to settle it outright.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More DSIP (Delta Sleep-Inducing Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.